PMID- 27232348
OWN - NLM
STAT- MEDLINE
DCOM- 20170223
LR  - 20170817
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 140
IP  - 6
DP  - 2016 Jun
TI  - Monitoring of the Clonal Fraction by Fluorescence In Situ Hybridization in 
      Myelodysplastic Syndrome: Comparison With International Working Group Treatment 
      Response Criteria.
PG  - 560-9
LID - 10.5858/arpa.2015-0150-OA [doi]
AB  - CONTEXT: -At the initial diagnosis of myelodysplastic syndrome (MDS) and/or 
      during follow-up, the evaluation of chromosomal abnormalities is based on 
      standard G-banding, whereas the utility of fluorescence in situ hybridization 
      (FISH) is still debated. OBJECTIVES: -To investigate whether interphase 
      fluorescence in situ hybridization (iFISH) clone size at initial diagnosis of MDS 
      is correlated with survival and whether changes in clonal fraction by iFISH are 
      concordant with the MDS International Working Group response criteria during 
      follow-up. DESIGN: -A tailored FISH panel (-5/5q-, -7/7q-, +8, -20/20q-, and 
      +1/1q+), based on reported cytogenetic changes in Korean patients with MDS, was 
      performed in 81 patients with MDS at initial diagnosis and in 28 patients during 
      follow-up. RESULTS: -During follow-up, absolute increases in the clone size by 
      iFISH by 20% or more, with relative increases of 50% or more, compared with 
      previous specimens, were associated with transformation to acute myeloid leukemia 
      (P = .001 and P = .002, respectively). Of the 28 patients with abnormal iFISH 
      results, 7 (25%) showed discordance between iFISH and MDS International Working 
      Group responses. Concordance between clone size by G-banding and iFISH was higher 
      in the refractory cytopenia with unilineage dysplasia/refractory cytopenia with 
      multilineage dysplasia group during follow-up, whereas the group with refractory 
      anemia with excess blasts showed higher correlation at initial diagnosis. 
      CONCLUSIONS: -We conclude that iFISH can provide additional prognostic 
      information and can predict the response to therapy in MDS.
FAU - Park, Jae Hyeon
AU  - Park JH
AD  - From the Departments of Laboratory Medicine (Drs Park and Lee), Internal Medicine 
      (Dr Yoon), and the Cancer Research Institute (Drs Yoon and Lee), Seoul National 
      University College of Medicine, Seoul, Korea; Department of Laboratory Medicine, 
      National Cancer Center, Goyang-si, Korea (Dr Kong); and the Department of 
      Laboratory Medicine, Hallym University College of Medicine, Anyang, Korea (Dr 
      Kim).
FAU - Kim, Miyoung
AU  - Kim M
FAU - Kong, Sun-Young
AU  - Kong SY
FAU - Yoon, Sung-Soo
AU  - Yoon SS
FAU - Lee, Dong Soon
AU  - Lee DS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Aberrations
MH  - Cytogenetic Analysis
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*genetics/mortality
MH  - Prognosis
MH  - Survival Rate
MH  - Young Adult
EDAT- 2016/05/28 06:00
MHDA- 2017/02/24 06:00
CRDT- 2016/05/28 06:00
PHST- 2016/05/28 06:00 [entrez]
PHST- 2016/05/28 06:00 [pubmed]
PHST- 2017/02/24 06:00 [medline]
AID - 10.5858/arpa.2015-0150-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2016 Jun;140(6):560-9. doi: 10.5858/arpa.2015-0150-OA.